Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study
EB Garon, KB Winfree, C Molife, ZL Cui… - Supportive Care in …, 2021 - Springer
Purpose In REVEL, patients with advanced non-small-cell lung cancer (aNSCLC) and
patients with increased tumor aggressiveness (rapid disease progression (RDP), platinum …
patients with increased tumor aggressiveness (rapid disease progression (RDP), platinum …
[HTML][HTML] Outcomes in patients with aggressive or refractory disease from REVEL: a randomized phase III study of docetaxel with ramucirumab or placebo for second …
M Reck, L Paz-Ares, P Bidoli, F Cappuzzo, S Dakhil… - Lung Cancer, 2017 - Elsevier
Objectives The REVEL study demonstrated improved efficacy for patients with advanced
non-small cell lung cancer treated with ramucirumab plus docetaxel, independent of …
non-small cell lung cancer treated with ramucirumab plus docetaxel, independent of …
Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study
DH Lee, H Isobe, H Wirtz, SB Aleixo, P Parente… - BMC Health Services …, 2018 - Springer
Background Data are scarce regarding real-world health care resource use (HCRU) for non-
small cell lung cancer (NSCLC). An understanding of current clinical practices and HCRU is …
small cell lung cancer (NSCLC). An understanding of current clinical practices and HCRU is …
Treatment outcomes by histology in REVEL: a randomized phase III trial of ramucirumab plus docetaxel for advanced non-small cell lung cancer
LG Paz-Ares, M Pérol, TE Ciuleanu, RD Kowalyszyn… - Lung Cancer, 2017 - Elsevier
Objectives Ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody
inhibiting vascular endothelial growth factor receptor-2, increased overall survival (OS) …
inhibiting vascular endothelial growth factor receptor-2, increased overall survival (OS) …
Healthcare Resource Utilization in Patients Receiving Pembrolizumab or Docetaxel with Previously Treated Advanced NSCLC
M Huang, J Pellissier, J Liao - Value in Health, 2016 - valueinhealthjournal.com
Objectives The objective of this study was to evaluate healthcare resource utilization
(HCRU) related to cancer management care within a clinical trial in advanced NSCLC …
(HCRU) related to cancer management care within a clinical trial in advanced NSCLC …
Association of baseline symptom burden with efficacy outcomes: exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung …
M Pérol, KB Winfree, GC Carter, ZL Cui, L Bowman… - Lung Cancer, 2019 - Elsevier
Objectives The REVEL study demonstrated improved efficacy with ramucirumab plus
docetaxel versus placebo plus docetaxel for previously treated advanced/metastatic non …
docetaxel versus placebo plus docetaxel for previously treated advanced/metastatic non …
Efficacy and safety of ramucirumab with docetaxel versus placebo with docetaxel as second-line treatment of advanced non–small-cell lung cancer: a subgroup …
SS Ramalingam, M Perol, M Reck, RD Kowalyszyn… - Clinical Lung Cancer, 2018 - Elsevier
Introduction Ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody
receptor antagonist designed to block the ligand-binding site of vascular endothelial growth …
receptor antagonist designed to block the ligand-binding site of vascular endothelial growth …
[PDF][PDF] Understanding total cost of care in advanced non-small cell lung cancer pre-and postapproval of immuno-oncology therapies
B Korytowsky, J Radtchenko, ED Nwokeji… - Am J Manag …, 2018 - ajmc.s3.amazonaws.com
REPORT reporting patterns of care and costs prior to the approval of targeted and IO
therapies. In addition, many of the published findings are not generalizable, as they …
therapies. In addition, many of the published findings are not generalizable, as they …
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non …
M Pérol, TE Ciuleanu, O Arrieta, K Prabhash… - Lung Cancer, 2016 - Elsevier
Objectives REVEL demonstrated that ramucirumab+ docetaxel (RAM+ DTX) improved
overall survival, progression-free survival, and objective response rate in patients with …
overall survival, progression-free survival, and objective response rate in patients with …
Real-world tumor response (rwTR) to ramucirumab plus docetaxel (R+ D) post platinum-based (Pt) and immune checkpoint inhibitor (ICI) therapy in advanced non …
JM Clarke, R Mathur, C Molife, M Batus, VJ Stefaniak… - 2019 - ascopubs.org
e20725 Background: In REVEL, adding ramucirumab to docetaxel improved response rates
among Pt-treated aNSCLC pts. This observational study evaluated rwTR in aNSCLC pts …
among Pt-treated aNSCLC pts. This observational study evaluated rwTR in aNSCLC pts …